Should I Buy LCTX? LCTX 2026 Analysis

Should You Buy Lineage Cell Therapeutics Inc (LCTX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

1.700

1 Day change

1.19%

52 Week Range

2.090

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Buy now (speculative): Technicals are turning up (positive/expanding MACD) and options positioning is aggressively bullish (very low put/call ratios).
Near-term trade setup: With pre-market around 1.71 and key resistance at 1.755 (R1) then 1.838 (R2), the risk/reward favors a push to resistance if momentum holds.
Why it works for an impatient buyer: There’s no need to wait for a “perfect” pullback—price is still close to the 1.622 pivot with defined supports below.

Intellectia Proprietary Trading Signals

AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.

Technical Analysis

Trend/Momentum: MACD histogram 0.00944 and positively expanding → bullish momentum building.
RSI: RSI(6) 65.07 → leaning bullish but not yet extreme; supports continuation potential.
Moving averages: Converging MAs → compression that often precedes a directional move; MACD suggests upside bias.
Key levels:
- Pivot: 1.622 (important decision level)
- Resistance: 1.755 (R1), 1.838 (R2)
- Support: 1.488 (S1), 1.405 (S2)
Context: Pre-market -1.72% while S&P 500 pre-market -0.82% → mild relative weakness today, but structure remains constructive above pivot.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/Sentiment: Open interest put/call 0.03 (calls dominate) → strongly bullish positioning.
Flow today: Put volume essentially 0 and call volume 157 → one-sided bullish tape.
Volatility: 30D IV 165.89 vs HV 63.52 → options pricing implies large moves; sentiment is bullish but expectations are elevated.
IV percentile/rank: IV percentile 64.14 (upper-mid) and IV rank 18.36 (not extremely high vs its own history) → elevated but not maxed.
Liquidity note: Today’s volume (157) is below 5D/10D avg (~429/457) → sentiment is clear, but activity isn’t surging today.

Technical Summary

Sell

Buy

Positive Catalysts

- Roche/OpRegen catalyst: H.C. Wainwright highlights the key breakout catalyst as Roche visibility on OpRegen data and next steps; a recent $5M milestone is cited as progress.
- Options sentiment: Extremely call-heavy open interest and volume ratios suggest traders are positioned for upside.
- Pattern-based odds: Similar-pattern analysis indicates a modest upward drift potential (next day/week/month probabilities skew positive).

Neutral/Negative Catalysts

- Event timing risk: The biggest upside driver (Roche clarity on OpRegen) is catalyst-dependent and timing is uncertain.
- Today’s tape: Pre-market weakness vs the broad market may cap early momentum.
- News relevance: The provided news is largely sector/market-wide regenerative medicine commentary, not a direct company-specific positive catalyst for LCTX in the near term.

Financial Performance

Latest quarter: 2025/Q3
- Revenue: $3.681M, -2.59% YoY (top-line soft).
- Net income: -$29.781M, improved +881.58% YoY (loss narrowed materially vs prior year).
- EPS: -0.13, improved +550% YoY.
- Gross margin: 99.86%, up 0.88% YoY.
Takeaway: Revenue is slightly down, but profitability metrics improved sharply YoY—consistent with a biotech improving cost/structure while waiting on clinical/partner catalysts.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Latest analyst update (2025-11-24): H.C. Wainwright reiterated Buy with a $9 price target.
What Wall Street is emphasizing (pros): Breakout potential tied to Roche’s OpRegen program progress, milestone validation, and expectation of advancement into later-stage studies.
Cons / what skeptics would cite: Heavy dependence on a partner-driven catalyst (Roche visibility/decisions) and limited near-term fundamental revenue growth signals.
Hedge funds / insiders: Both Neutral with no notable recent trend.
Politicians/Congress: No recent congress trading data available (no evidence of political accumulation/distribution from the provided data).

4 Analyst Rating

Wall Street analysts forecast LCTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LCTX is 4.5 USD with a low forecast of 3 USD and a high forecast of 9 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

0 Hold

0 Sell

Strong Buy

Current: 1.680

Low

Averages

4.5

High

Current: 1.680

Low

Averages

4.5

High

H.C. Wainwright

Buy

maintain

AI Analysis

2025-11-24

Reason

H.C. Wainwright

Price Target

AI Analysis

2025-11-24

maintain

Buy

Reason

H.C. Wainwright reiterated a Buy rating and $9 price target on Lineage Cell Therapeutics (LCTX), saying the major breakout event the firm is looking for is visibility out of global partner Roche (RHHBY) regarding OpRegen data and next steps. Monday's $5M milestone represents yet another tangible piece of evidence for Roche's progress in the OpRegen program for which they have global rights for dry-AMD and geographic atrophy, the analyst tells investors in a research note. The firm added that data, anecdotes, and comps provide significant support that OpRegen is moving into later studies in Roche's hands.

B. Riley Securities

Mayank Mamtani

Strong Buy

Maintains

$4 → $3

2025-03-14

Reason

B. Riley Securities

Mayank Mamtani

Price Target

$4 → $3

2025-03-14

Maintains

Strong Buy

Reason

B. Riley analyst Mayank Mamtani lowered the firm's price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the shares. Lineage Cell Therapeutics' Q4 recap focused on Roche (RHHBY)-partnered OpRegen program, steadily advancing earlier-stage wholly-owned programs, and Lineage's dominant position in large-scale allogeneic manufacturing to produce millions of retinal pigment epithelium cells, the analyst tells investors in a research note. The OpRegen dry AMD opportunity could come through the ongoing Phase II GAlette study interim data release, and Roche opting to progress to a randomized controlled study to confirm high efficacy benefits noted with optimized delivery system in sizeable patient population, the firm says.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LCTX

Unlock Now

LCTX Should I Buy

LCTX Should I Buy

Should You Buy Lineage Cell Therapeutics Inc (LCTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch